Pretreatment with Tetramethylpyrazine Increases the Release of PGI2 and Decreases TXA2 Release in Isolated Rat Heart

Jun Feng; Ruiyan Liu; Guozhen Wu; Shuben Tang

doi:10.1055/s-2006-957915

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000058.xml

Share / Bookmark

Facebook X Linkedin Weibo

Download PDF

Planta Med 1996; 62(4): 379-381
DOI: 10.1055/s-2006-957915

Letters

Pretreatment with Tetramethylpyrazine Increases the Release of PGI₂ and Decreases TXA₂ Release in Isolated Rat Heart

Jun Feng¹ , Ruiyan Liu² , Guozhen Wu³ , Shuben Tang⁴

¹Department of Physiology, Faculty of Medicine, Research Center of Sacre-Coeur Hospital, University of Montreal, 5400 Gouin Blvd. West, Montréal, Québec, Canada H4J 1C5
²Department of Cardiology, First Teaching Hospital, Henan Medical University, Zhengzhou, P. R. China
³Department of Thoracic and Cardiovascular Surgery, First Teaching Hospital, Henan Medical University, Zhengzhou, P. R. China
⁴Department of Physiology, Henan Medical University, Zhengzhou, P. R. China

Further Information

Publication History

1995

1996

Publication Date:
04 January 2007 (online)

PDF Download Permissions and Reprints

Abstract

We investigated the release of PGI₂ and TXA₂ by measuring their stable metabolites of 6-keto-PGF_1a and TXB₂ in the perfusate in the isolated rat heart after pretreatment with tetramethylpyrazine (TMP). Pretreatment with TMP (12 mg/kg, i.p.) 7 days before preparation produced a significant elevation of 6-keto-PGF_1a from 2.30 ± 0.65 ng/min/g of untreated controls to 3.8 ± 0.77 ng/min/g (p < 0.05). Pretreatment with TMP also decreased TXB₂ release (p < 0.05 versus control).

>